Cancer is a class of diseases in which a group of cells display new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments.

3D reconstruction of a polarized mammary epithelial acinus with a hollow lumen in the middle. Image courtesy of Professor Charles Streuli and Dr. Nasreen Akhtar, University of Manchester, UK.

Cancer research is an intense scientific effort to understand and discover disease processes and discover possible therapies. Cellular imaging has revolutionized cancer biology by enabling cells to be seen more clearly and in more detail as well as creating meaningful functional assays for the development of drugs which prevent tumor growth and metastasis. Advanced cellular imaging techniques allow us to visualize important aspects of cancer including tumor cell mobility, invasion, metastasis and angiogenesis.

Scientists can distinguish host cells from a tumor with single-cell resolution. Visualization of many aspects of cancer initiation and progression in vivo is now possible, providing greater context and more accuracy to cancer research.

PerkinElmer provides powerful imaging and high content screening solutions to cancer researchers globally. Complete solutions are available through a dedicated team of imaging specialists who fully understand the imaging requirements of cancer research applications and will help guide you all the way from selecting the right solution to publishing your results.

Customer Stories

Cancer-killing Seaweed

Publications using PerkinElmer High-Content Screening Products

• A, Guzman M, Rodriguez O and Grueso J. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 2016; 76:2301-2313.
• Alexander C-M, Xiong K-N, Velmurugan K, Xiong J, Osgood RS and Bauer AK. Differential innate immune cell signatures and effects regulated by toll-like receptor 4 during murine lung tumor promotion. Experimental Lung Research. 2016; 42:154-173.
• Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G and Schwenkert M. A novel approach for targeted elimination of CSPG4‐ positive triple‐negative breast cancer cells using a MAP tau‐based fusion protein. International Journal of Cancer. 2016; 139(4):916-27.
• Bauer AK, Velmurugan K, Xiong KN, Alexander CM, Xiong J and Brooks R. Epiregulin is required for lung tumor promotion in a murine two‐stage carcinogenesis model. Molecular carcinogenesis. 2016, doi: 10.1002/mc.22475.
• Falkenberg N, Höfig I, Rosemann M, Szumielewski J, Richter S, Schorpp K, Hadian K, Aubele M, Atkinson MJ and Anastasov N. Three‐dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer. Cancer Medicine. 2016, 5(4):703-10.
• Flinders C, Lam L, Rubbi L, Ferrari R, Fitz-Gibbon S, Chen P-Y, Thompson M, Christofk H, Agus D and Ruderman D. Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Medicine. 2016; 8(1):54.
• Kumar CS, Mahesh A, Antoniraj MG, Vaidevi S and Ruckmani K. Ultrafast synthesis of stabilized gold nanoparticles using aqueous fruit extract of Limonia acidissima L. and conjugated epirubicin: targeted drug delivery for treatment of breast cancer. RSC Advances. 2016; 6:26874-26882.
• Lange I, Moschny J, Tamanyan K, Khutsishvili M, Atha D, Borris RP and Koomoa D-L. Scrophularia orientalis extract induces calcium signaling and apoptosis in neuroblastoma cells. International Journal of Oncology. 2016; 48(4):1608-1616.
• Perlíková P, Rylová G, Nauš P, Elbert T, Tloušťová E, Bourderioux A, Slavětínská LP, Motyka K, Doležal D and Znojek P. 7-(2-Thienyl)-7-deazaadenosine (AB61), a new potent nucleoside cytostatic with a complex mode of action. Molecular Cancer Therapeutics. 2016;15(5):922-937.
• Schang G, Robaire B and Hales BF. Organophosphate Flame Retardants act as Endocrine-Disrupting Chemicals in MA-10 Mouse Tumor Leydig Cells.Toxicological Sciences. 2016, 150(2):499-509.
• Weber C, Telerman SB, Reimer AS, Sequeira I, Liakath-Ali K, Arwert EN and Watt FM. Macrophage infiltration and alternative activation during wound healing promote MEK1-induced skin carcinogenesis. Cancer Research. 2016; 76(4):805-17.
• Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P and Bader B. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Molecular Cancer Therapeutics. 2016; 15(4):583-592.
• Zhou Q, Abraham A, Li L, Babalmorad A, Bagby S, Arcaroli J, Hansen R, Valeriote F, Gustafson D and Schaack J. Topoisomerase IIα mediates TCF-dependent epithelial–mesenchymal transition in colon cancer. Oncogene. 2016, doi: 10.1038/onc.2016.29.
• Anastasov N, Höfig I, Radulović V, Ströbel S, Salomon M, Lichtenberg J, Rothenaigner I, Hadian K, Kelm JM and Thirion C. A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment. BMC Cancer. 2015; 15:466.
• Bastian A, Thorpe JE, Disch BC, Bailey-Downs LC, Gangjee A, Devambatla RK, Henthorn J, Humphries KM, Vadvalkar SS and Ihnat MA. A Small Molecule with Anticancer and Antimetastatic Activities Induces Rapid Mitochondrial-Associated Necrosis in Breast Cancer. Journal of Pharmacology and Experimental Therapeutics. 2015; 353(2):392-404.
• Bao B, Liu M, Liu Y, Zhang X, Zang Y, Li J and Lu W. NIR absorbing DICPO derivatives applied to wide range of pH and detection of glutathione in tumor. Tetrahedron. 2015; 71(41):7865-7868.
• Bill R, Fagiani E, Zumsteg A, Antoniadis H, Johansson D, Haefliger S, Albrecht I, Hilberg F and Christofori G. Nintedanib is a highly effective therapeutic for neuroendocrine carcinoma of the pancreas (PNET) in the Rip1Tag2 transgenic mouse model. Clinical Cancer Research. 2015: 21(21):4856-67.
• Cheng V, Esteves F, Chakrabarty A, Cockle J, Short S and Brüning-Richardson A. High-content analysis of tumour cell invasion in three-dimensional spheroid assays. Oncoscience. 2015; 2(6):596-606.
• Cursons J, Leuchowius K-J, Waltham M, Tomaskovic-Crook E, Foroutan M, Bracken CP, Redfern A, Crampin EJ, Street I and Davis MJ. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Communication and Signaling. 2015;13:26.
• Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, Rosemann M and Aubele M. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. Molecular Oncology. 2015; 9(1):282-294.